Medication info

Rinatone M Tablet 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Korea Pavis Pharmaceutical Co., Ltd.
Appearance
Bright orange, oval-shaped film-coated tablet with a convex surface on both sides
Packaging
60 tablets (10 tablets/PTP) x 6
Approval status
Active

MFDS item code 201903571 · Approved 2019.05.30

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their current doses of linagliptin and metformin. 4. Patients whose blood glucose is inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Administration with caution in the following patients). 5. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, provided the following dosage adjustments are made. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Do not administer to the following patients).

Ingredients

Manufacturer
Korea Pavis Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used for adults with type 2 diabetes to improve blood sugar control in conjunction with dietary and exercise therapy. It can be administered to those who have never taken diabetes medications before or whose blood sugar control is insufficient with monotherapy. Additionally, it is added in cases where blood sugar control is difficult with metformin monotherapy or combination therapy with other diabetes drugs (such as sulfonylureas, empagliflozin, insulin, etc.). This medication is useful in enhancing blood sugar control effects when used alongside multiple therapies. It effectively improves blood sugar levels with a suitable blood sugar control method tailored to the patient's condition.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their current doses of linagliptin and metformin. 4. Patients whose blood glucose is inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Administration with caution in the following patients). 5. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, provided the following dosage adjustments are made. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Do not administer to the following patients).

Precautions

This medication can cause a rare but serious side effect called lactic acidosis; therefore, patients with impaired kidney function or issues with heart or liver functions should not use it. Additionally, it should be avoided in patients with allergies to any ingredients of this medication or those with specific conditions such as type 1 diabetes, diabetic ketoacidosis, or acute myocardial infarction. As there is a risk of hypoglycemia, caution is needed when used with other antidiabetic agents such as insulin or sulfonylureas, and dosage adjustments may be necessary. Patients with decreased kidney function should have their kidney function tested periodically, and the medication should be temporarily discontinued under circumstances that pose a risk of acute kidney injury. This medication can cause skin conditions such as acute pancreatitis or bullous pemphigoid; therefore, if severe abdominal pain or skin abnormalities occur during treatment, consult a doctor immediately. It may lower vitamin B12 levels, so it's important to check for vitamin B12 deficiency during long-term use. Pregnant or nursing women should avoid using this medication, and it is not recommended for children and adolescents. Elderly patients often experience reduced kidney function, so adequate dosage adjustments and regular monitoring of kidney function are needed. This medication can interact with various drugs; therefore, inform your doctor or pharmacist if you are taking other medications. In case of overdose, there is a risk of lactic acidosis, and you should seek medical treatment immediately, possibly necessitating hemodialysis. Store this medication out of the reach of children, in a place avoiding moisture, and in its original container.

Side effects

Lactic Acidosis, Pharyngitis, Hypersensitivity, Angioedema, Urticaria, Decreased and Deficiency of Vitamin B12, Hypoglycemia, Dysgeusia, Cough, Appetite Loss, Diarrhea, Constipation, Nausea, Pancreatitis, Vomiting, Abdominal Pain, Oral Ulcer Formation, Liver Function Test Abnormalities, Hepatitis, Pruritus, Erythema, Rash, Bullous Pemphigoid, Severe Joint Pain Accompanied by Disability, Rhabdomyolysis, Increased Lipase, Increased Amylase, Upper Abdominal Pain, Enterocolitis, Intestinal Obstruction, Gastroenteritis, Herpes Zoster, Cystitis, Acute Pyelonephritis, Bronchitis, Vestibular Neuronitis, Sepsis, Pneumonia, Constipation, Upper Abdominal Pain, Dyspepsia, Stomatitis, Abdominal Pain, Gastrointestinal Disorders, Irritable Bowel Syndrome, Oral Burning Sensation Syndrome, Colitis, Abdominal Discomfort, Dysphagia, Gastric Ulcer, Gum Bleeding, Intestinal Obstruction, Tooth Loss, Hemorrhoids, Lower Abdominal Pain, Gastritis, Gastrointestinal Disorders, Irritable Bowel Syndrome, Acute Pyelonephritis, Bronchitis, Lichen Planus, Rhinitis, Soft Tissue Infection, Pharyngitis, Vestibular Neuronitis, Scrub Typhus, Periodontitis, Tonsillitis, Laryngitis, Viral Upper Respiratory Infection, Pneumonia, Tonsillitis, Appetite Loss, Hypercholesterolemia, Inadequate Control of Diabetes, Malnutrition, Hyponatremia, Dehydration, Hyperglycemia, Inadequate Control of Diabetes, Cerebral Infarction, Diabetic Neuropathy, Headache, Articulation Disorder, Sensory Abnormalities, Postherpetic Neuralgia, Hemiplegia, Syncope, Alzheimer's Dementia, Drowsiness, Fatigue, Chest Discomfort, Lack of Strength, Death, Pain, Nosebleed, Oropharyngeal Pain, Chronic Obstructive Pulmonary Disease, Voice Disorder, Allergic Rhinitis, Exertional Dyspnea, Wet Cough, Asthma, Runny Nose, Pulmonary Mass, Joint Pain, Osteoporosis, Arthropathy, Musculoskeletal Discomfort, Myositis, Myalgia, Soft Tissue Mass, Postmenopausal Osteoporosis, Rotator Cuff Syndrome, Increased Blood Triglycerides, Increased Urine Albumin/Creatinine Ratio, Positive Urine Leukocytes, Decreased Hemoglobin, Increased Blood Potassium, Increased Blood Creatinine, Increased Blood Creatine Phosphokinase, Male Pattern Baldness, Diabetic Foot, Hyperhidrosis, Hair Loss, Skin Lesions, Dermatitis, Liver Metastasis, Acute Leukemia, Basal Cell Carcinoma, Non-Small Cell Lung Cancer, Malignant Pericardial Effusion, Benign Duodenal Neoplasm, Benign Skin Neoplasm, Stomach Cancer, Rectal Cancer, Pancreatic Cancer, Anxiety, Mood Disorder, Insomnia, Depression, Contusion, Bone Bruise, Concussion, Meniscus Injury, Foot Fracture, Hand Fracture, Pneumoconiosis, Laceration, Congestive Heart Failure, Angina, Acute Myocardial Infarction, Palpitations, Unstable Angina, Cardiac Arrest, Diabetic Retinopathy, Dry Eye, Glaucoma, Cataract, Ocular Discomfort, Allergic Conjunctivitis, Acute Kidney Injury, Polyuria, Proteinuria, End-Stage Renal Disease, Stress Urinary Incontinence, Hematuria, Hypotension, Flushing, Hepatic Steatosis, Acute Cholangitis, Acute Cholecystitis, Cholangiitis, Cholelithiasis, Hearing Loss, Dizziness, Erectile Dysfunction, Goiter, Kidney Transplant Failure, Anemia, Itching, Insomnia, Depression, Hypertension, Benign Prostatic Hyperplasia, Angina, Acute Myocardial Infarction, Unstable Angina, Diarrhea, Pancreatitis, Stomatitis, Mediastinitis, Pneumonia, Rhinitis, Vitreous Hemorrhage, Fever, Ligament Sprain, Flank Pain, Myelodysplastic Syndrome, Vocal Cord Polyp, Dyspepsia, Anal Bleeding, Cheilitis, Tooth Decay, Enteritis, Gastritis, Confusion, Nocturia, Dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container while in use. Additionally, avoid storing it in places that are too hot or too cold, and it is recommended to keep it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Bright orange, oval-shaped film-coated tablet with a convex surface on both sides

Package unit

60 tablets (10 tablets/PTP) x 6

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.